Tyme Technologies, Inc. (NASDAQ:TYME) reached yearly low touching $1.89. Our price target is $1.73. On Mar, 27 it was published by Barchart.com. It has $194.98 million MC. $15.60 million less could be NASDAQ:TYME valuation at $1.73 share price.

Ticker’s shares touched $1.885 during the last trading session after 9.37% change.Tyme Technologies, Inc. has volume of 386,537 shares. Since March 27, 2018 TYME has declined 15.16% and is downtrending. TYME underperformed by 19.53% the S&P 500.

Tyme Technologies, Inc. (NASDAQ:TYME) is expected to report earnings on June, 12., according to RTT. Analysts forecast 33.33 % diference or $-0.08 from the $-0.06 EPS from 2018. 0.00 % EPS growth is what analysts predict. $-0.08 EPS was announced for previous quarter.

For more Tyme Technologies, Inc. (NASDAQ:TYME) news announced recently go to: Globenewswire.com, Seekingalpha.com, Globenewswire.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Pawar Law Group Reminds Investors of March 29 Deadline in Securities Class Action Lawsuit Against Tyme Technologies, Inc. – TYME – GlobeNewswire” announced on March 21, 2019, “Tyme down 48% on SM-88 data – Seeking Alpha” on January 18, 2019, “Tyme Technologies To Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019 – GlobeNewswire” with a publish date: March 11, 2019, “CLASS ACTION UPDATE for GSM, TYME, MHLD and BRS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders – GlobeNewswire” and the last “TYME DEADLINE ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Tyme Technologies, Inc. – TYME – GlobeNewswire” with publication date: March 12, 2019.

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications.The firm is valued at $194.98 million. It is developing SM-88, a combination therapy in Phase II development for prostate cancer.Currently it has negative earnings.